Liraglutide for type 2 diabetes mellitus

Bibliography

• International Diabetes Federation. The diabetes atlas. 4th edition. International Diabetes Federation; Brussels: 2009
   Google Scholar
• Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
   PubMed Web of Science ®Google Scholar
• Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002;11:279-84
   Web of Science ®Google Scholar
• Cramer JA. A systematic review of adherence with medications for diabetes. Diabetes Care 2004;27:1218-24
   PubMed Web of Science ®Google Scholar
• Brown JB, Nichols GA, Glauber HS, Bakst A. Ten-year follow-up of antidiabetic drug use, nonadherence, and mortality in a defined population with type 2 diabetes mellitus. Clin Ther 1999;21:1045-57
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
   PubMed Web of Science ®Google Scholar
• Fox KM, Gerber RA, Bolinder B, Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-95
   PubMed Web of Science ®Google Scholar
• Hoerger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-6
   PubMed Web of Science ®Google Scholar
• McFarlane SI, Jacober SJ, Winer N, Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care 2002;25:718-23
   PubMed Web of Science ®Google Scholar
• Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003;26:2929-40
   PubMed Web of Science ®Google Scholar
• Holst J. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006;49:253-60
   PubMed Web of Science ®Google Scholar
• Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007;132:2131-57
   PubMed Web of Science ®Google Scholar
• Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-30
   PubMed Web of Science ®Google Scholar
• Russell-Jones D. Current developments in the treatment of diabetes: the incretin therapies. Br J Diabetes Vasc Dis 2010;10:21-30
   Google Scholar
• Available from: http:www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000698/human_med_000682.jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d125. [Last accessed 17 December 2010]
   Google Scholar
• Hendry J. FDA approves exenatide. DOC News 2005;2:1-6
   Google Scholar
• DeFronzo RA, Ratner RE, Han J, Effects of exenatide (Exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-100
   PubMed Web of Science ®Google Scholar
• Kendall DM, Riddle MC, Rosenstock J, Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-91
   PubMed Web of Science ®Google Scholar
• Buse JB, Henry RR, Han J, Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-35
   PubMed Web of Science ®Google Scholar
• Zinman B, Hoogwerf BJ, Duran Garcia S, The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes. Ann Intern Med 2007;146:477-85
   PubMed Web of Science ®Google Scholar
• Kolterman OG, Buse JB, Fineman MS, Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003;88:3082-9
   PubMed Web of Science ®Google Scholar
• Klonoff DC, Buse JB, Nielsen LL, Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2007;24:275-86
   Web of Science ®Google Scholar
• Moretto TJ, Milton DR, Ridge TD, Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008;30:1448-60
   PubMed Web of Science ®Google Scholar
• Barnett AH, Burger J, Johns D, Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. Clin Ther 2007;29:2333-48
   PubMed Web of Science ®Google Scholar
• Davies MJ, Donnelly R, Barnett AH, Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. Diabetes Obes Metab 2009;11:1153-62
   PubMed Web of Science ®Google Scholar
• Heine RJ, Van Gaal LF, Johns D, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005;143:559-69
   PubMed Web of Science ®Google Scholar
• Nauck MA, Duran S, Kim D, A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-67
   PubMed Web of Science ®Google Scholar
• Blevins T, Han J, Nicewarner D, Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. Postgrad Med 2010;122:118-28
   PubMed Web of Science ®Google Scholar
• Buse JB, Bergenstal RM, Glass LC, Use of twice-daily exenatide in basal insulin-treated patients with type 2 diabetes: a randomized, controlled trial. Ann Intern Med 2010; published online, doi:0003-4819-154-2-201101180-00300 [pii]; 10.1059/0003-4819-154-2-201101180-00300 [doi]
   PubMedGoogle Scholar
• Monami M, Marchionni N, Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009;160:909-17
   PubMed Web of Science ®Google Scholar
• Buse JB, Rosenstock J, Sesti G, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47
   PubMed Web of Science ®Google Scholar
• Garber A, Henry R, Ratner R, Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81
   PubMed Web of Science ®Google Scholar
• Marre M, Shaw J, Brandle M, Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabet Med 2009;26:268-78
   PubMed Web of Science ®Google Scholar
• Nauck M, Frid A, Hermansen K, Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes. Diabetes Care 2009;32:84-90
   PubMed Web of Science ®Google Scholar
• Russell-Jones D, Vaag A, Schmitz O, Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-55
   PubMed Web of Science ®Google Scholar
• Zinman B, Gerich J, Buse JB, Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD). Diabetes Care 2009;32:1224-30
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Buse JB, Taylor K, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008;372:1240-50
   PubMed Web of Science ®Google Scholar
• Diamant M, Van GL, Stranks S, Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet 2010;375:2234-43
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Wysham C, Macconell L, Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010;376:431-9
   PubMed Web of Science ®Google Scholar
• Buse JB, Drucker DJ, Taylor KL, DURATION-1: exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33:1255-61
   PubMed Web of Science ®Google Scholar
• Amylin, Lilly and Alkermes Announce Receipt of Complete Response Letter from FDA for BYDUREON(TM). Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol-newsArticle&ID=1484584. [Last accessed 17 December 2010]
   Google Scholar
• Steensgaard D, Thomsen J, Olsen H, Knudsen LB. The Molecular basis for the delayed absorption of the once-daily human glp-1 analogue, liraglutide. Diabetes 2008;57(Suppl 1):A164
   Google Scholar
• Liraglutide Summary of Product Characteristics. Available from: http://www.medicines.org.uk/EMC/medicine/21986/SPC/Victoza+6+mg+ml+solution+for+injection+in+pre-filled+pen. [Last accessed 17 December 2010]
   Google Scholar
• Agerso H, Jensen LB, Elbrond B, The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002;45:195-202
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Gumprecht J, Szyprowska E, Pharmacokinetics of liraglutide vs exenatide in type 2 diabetes: sustained vs fluctuating concentrations over 24 hours. Diabetes 2009;58(Suppl 1):A150
   Google Scholar
• Davidson J, Falahati A, Brett J. Mild renal impairment has no effect on the efficacy and safety of liraglutide [abstract 235]. AACE; 2009
   Google Scholar
• Madsbad S, Schmitz O, Ranstam J, Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211). Diabetes Care 2004;27:1335-42
   PubMed Web of Science ®Google Scholar
• Vilsboll T, Zdravkovic M, Le Thi T, Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007;30:1608-10
   PubMed Web of Science ®Google Scholar
• Holst J, Nauck M, Brett J, Improvement in glycaemic control when adding liraglutide to existing therapy: results from a meta-analysis of six large randomised clinical trials. Diabetologia 2009;52(Suppl 1):S288
   Google Scholar
• Schmidt W, Gough S, Madsbad S, Liraglutide, a human GLP-1 analogue, lowers HbA1c independent of weight loss. Diabetologia 2009;52(Suppl 1):S289
   PubMedGoogle Scholar
• Fonseca V, Madsbad S, Falahati A, Once-daily human GLP-1 analog liraglutide reduces systolic blood pressure – a meta-analysis of 6 clinical trials. Diabetes 2009;58(Suppl 1):A146
   PubMed Web of Science ®Google Scholar
• Zinman B, Buse J, Falahati A, Moses A. Attaining a clinically relevant endpoint of HbA1c <7.0%, no weight gain and no hypoglycaemia with liraglutide as compared to other therapies in type 2 diabetes mellitus: a meta-analysis of the LEAD studies. Diabetologia 2009;52(Suppl 1):S291
   Google Scholar
• Zinman B, Buse J, Falahati A, Liraglutide more effectively achieves a composite endpoint for A1C, SBP and weight change than other diabetes therapies. Diabetes 2009;58(Suppl 1):A143
   Google Scholar
• Buse JB, Sesti G, Schmidt WE, Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010;33:1300-3
   PubMed Web of Science ®Google Scholar
• Pratley RE, Nauck M, Bailey T, Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010;375:1447-56
   PubMed Web of Science ®Google Scholar
• Montanya Mias E, Cuddihy R, Pratley R, Treatment satisfaction in patients with type 2 diabetes is significantly improved with liraglutide, the once-daily GLP-1 analogue versus sitagliptin, both combined with metformin. Diabetologia 2010;53(Suppl 1):S331
   PubMedGoogle Scholar
• Gallwitz B, Vaag A, Falahati A, Madsbad S. Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time. Int J Clin Pract 2010;64:267-76
   PubMed Web of Science ®Google Scholar
• Knudsen LB, Madsen LW, Andersen S, Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473-86
   PubMed Web of Science ®Google Scholar
• Liraglutide US Prescribing Information. Available from: http://www.victoza.com/pdf/Victoza_ComboPI_5.24.pdf. (Accessed 17 December 2010)
   Google Scholar
• Parks M, Rosebraugh C. Weighing risks and benefits of liraglutide–the FDA's review of a new antidiabetic therapy. N Engl J Med 2010;362:774-7
   PubMed Web of Science ®Google Scholar
• Davies MJ, Kela R, Khunti K. Liraglutide — overview of the preclinical and clinical data and its role in the treatment of type 2 diabetes. Diabetes Obes Metab 2010; published online 18 Nov 2010, DOI: 10.1111/j.1463-1326.2010.01330.x
   Web of Science ®Google Scholar
• Chatterjee DJ, Khutoryansky N, Zdravkovic M, Absence of QTc prolongation in a thorough QT study with subcutaneous liraglutide, a once-daily human GLP-1 analog for treatment of type 2 diabetes. J Clin Pharmacol 2009;49:1353-62
   PubMed Web of Science ®Google Scholar
• Holman RR, Paul SK, Bethel MA, 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-89
   PubMed Web of Science ®Google Scholar
• Stratton IM, Adler AI, Neil HA, Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59
   PubMed Web of Science ®Google Scholar
• Bonds DE, Miller ME, Bergenstal RM, The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010;340:b4909
   PubMed Web of Science ®Google Scholar
• Miller ME, Bonds DE, Gerstein HC, The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ 2010;340:b5444
   PubMed Web of Science ®Google Scholar
• National Insititute of health and Clinical Excellence. Liraglutide for treatment of type 2 diabetes mellitus- NICE technology appraisal guidance 203, October 2010. 2010
   Google Scholar
• Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results - A Long Term Evaluation (LEADER). ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01179048?term=LEADER&rank=3. [Accessed 17 December 2010]
   Google Scholar